DUSP22 and metabolic dysfunction-associated steatohepatitis: Finally, we surprisingly found that DUSP22 reduced tumor size and number in DEN/HFHC-induced mouse model with NASH-related HCC, which was validated by the decreased HCC cell proliferation in vitro, indicating that DUSP22 may act as a tumor suppressor to further restrain NASH development into HCC.